Pediatrix Medical Group, Inc. (NYSE:MD) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET
Corporate Participants
Charles Lynch – Investor Relations
Mark Ordan – Chief Executive Officer
Marc Richards – Chief Financial Officer
Conference Call Participants
Tao Qiu – Stifel
Brian Tanquilut – Jefferies
Kevin Fischbeck – Bank of America
Pito Chickering – Deutsche Bank
Whit Mayo – SVB Securities
Ryan Daniels – William Blair
AJ Rice – Credit Suisse
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Pediatrix Medical Group Second Quarter 2022 Earnings Conference Call. [Operator Instructions]. As a reminder, your call today is being recorded.
I would now turn the conference call over to your host, Charles Lynch. Please go ahead.
Charles Lynch
Thank you, Allen, and good morning, everyone. With me this morning are Mark Ordan, Chief Executive Officer and Marc Richards, our Chief Financial Officer. I will quickly read our disclaimer and then turn the call over to Mark.
Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and assessments made by Pediatrix’ management in light of their experience and assessment of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
Any forward-looking statements made during this call are made as of today, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the company’s most recent annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, including the sections entitled Risk Factors.
In today’s remarks by management, we will be discussing non-GAAP financial metrics. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures can be found in this morning’s earnings press release, our quarterly reports on Form 10-Q and our annual report on Form 10-K and on our website at www.pediatrix.com.
With that, I’ll turn the call over to Mark Ordan.
Mark Ordan
Thanks, Charlie.
I’ll comment this morning on three areas; our results for the quarter and how they play into our outlook for the year; our strategy and our name change to the Pediatrix Medical Group. And some thoughts on the No Surprises Act. We had mixed results in Q2. Patient volumes grew both in hospital based and office-based services despite more difficult comps in the second quarter to what we faced in the first quarter. However, our revenue was impacted by both payer mix and our ongoing transition to R1 as our RCM partner.
As a result, our adjusted EBITDA for the quarter was slightly below the expectations we shared on our last call with a differential primarily in revenue. We’re pleased with our RCM function today but in retrospect, the speed with which we transitioned from our internal team to R1 gave rise to a revenue impact that setback our Q1 results and to a lesser extent, our Q2 results. I want to stress that this impasse, I speak off and which Marc will further detail is related only to our RCM transition and not to any change in pay relationships or behavior. And we are pleased that today or day to day RCM function is substantially improved versus the challenges we faced during this transition.
By that I mean that our front-end activity is moving well, which is significant given that that area was meaningfully impacted in the early stages of this transition. Its impact should affect 2022 alone, and we see no effect therefore beyond this year. We are also still actively working to mitigate the effect on our 2022 P&L.
On clinical labor, we reported in Q1 that we had not seen any material change in clinical labor costs but was certainly aware of the tough environment around us. In Q2, our clinical salary costs were roughly 3 million above our forecast. While this is much smaller, a much smaller change in cost trend and other providers have discussed, I’m calling it out only given the tough labor environment we’re in. We continued to reduce overheads and generate efficiencies in our support services as part of our turnaround strategy.
Our G&A expense declined significantly compared to last year, and versus our internal projections and we believe that we will continue to find enhanced operating efficiency without taking away from our dedication to care. We also saved significantly to our Q1 debt refinancing interest expense was down more than half year-over-year enabling 50% growth in adjusted EPS. And finally, our strong cash flow enabled us to fund the repurchase of 3.3 million of our shares. Our CapEx and one acquisition without changing our debt levels.
The confluence of all the factors I’ve described thus far, leaders who expect that 270 million and adjusted EBITDA, for 2022 does remain achievable, but we now point to a range of between $260 million and $270 million for the year. I’ll turn to our growth and strategy.
All of our efforts are focused on women’s, children’s and baby’s health, and on our amazing affiliated clinicians who provide care, as well as the research, education, and quality and safety improvements required to be the leaders in their vital field. On July 1, we formally changed our name to Pediatrix Medical Group to underscore this complete focus.
Our move into a combination of pediatric primary and urgent care will help us serve this population much more broadly and effectively. I discussed last quarter that additions to our team under Dr. Jim Swift, our Chief Operating Officer, and we’re now fully underway in our growth plan between now and the end of 23, we anticipate we will expand from our current footprint of 21 clinics across three markets and Tuesdays between 40 to 50 clinics across eight to 10 markets in a half dozen states. We expected this growth will come from a combination of de novo clinic openings and acquisitions. We’re also confident that we can fund this growth with internally generated cash flow and we intend to execute in a fashion that will not dilute our adjusted EBITDA.
On the No Surprises Act as I mentioned earlier today, we haven’t seen any notable change in payer behavior related to out of network cases, we are still waiting for HHS to finalize the tools, guidance, the details of the arbitration process. That said, we’re certainly not sitting idle, our managed care team alongside our partners, and R1 have built a really robust capability to manage this arbitration process in a thoughtful data driven way. Here again, we’re much better prepared for this process than we could have been on our own.
Before I turn to call to Marc, I want to thank our affiliated clinicians, our operators and our support team for all their hard work and dedication to this organization. In my now two years at Pediatrix, I am really awestruck by what our people do for families across the nation. Marc?
MarcRichards
Thanks, Mark. Good morning, everyone.
I’ll focus my comments today on our revenue cycle management transition process. Then add to Mark’s comments on our outlook and financial position.
At the top-line, the decline in our same unit pricing was measurably less than we reported in Q1 when you exclude the contribution from CARES dollars in both periods. The revenue impact from the RCM related matters Mark discussed, which we bucket as a component of pricing was less than half the magnitude of the first quarter. We are roughly $5 million.
Payer mix, which can fluctuate quarter-to-quarter represented a headwind in Q2 versus a modest tailwind in Q1. Looking at RCM, our transition to R1 created an increase in accounts receivable and related reserves, which unfavorably affected our revenue in the first quarter and to a lesser degree, the second quarter of this year.
This AR build up continued beyond March, followed by a significant improvement in cash collections towards the end of the quarter. The impact related to our private pay business not managed by R1 was negligible for the quarter and is a small component of the $5 million I referenced.
All told, you’ll see in our press release in our 10-Q filed this morning that both our gross and net AR declined modestly for the quarter and DSOs came down by one day compared to March 31 to 58 days. We’re certainly pleased with this direction, but DSOs at quarter end are still higher than normal.
As of today, we view our RCM activities as bifurcated. As Mark noted, we are now running normal billing and collecting activity related to current patient services. Separately, we’re also working the more aged AR and will continue to do so through the remainder of the year. The pace and trajectory of this activity could represent a swing factor within our range of expected EBITDA for the year.
For modeling purposes, our 22 outlook reflects adjusted EBITDA in the first half of the year by 116.2 million. Additionally, within our outlook, we expect our adjusted EBITDA for the third quarter to Increase in the mid-single digit percent range compared to 73 million in the third quarter of 2021.
Lastly, we remain in a strong financial position. We generated $82 million in operating cash flow in the second quarter, up about 11 million year-over-year, funded 64 million in share repurchases, our normal CapEx and a small practice acquisition. At quarter end, our total debt of 800 million was effectively unchanged from March 31. And our leverage based on trailing 12 adjusted EBITDA was just under three times.
With that, I’ll turn the call back over to Mark.
Mark Ordan
Thanks, Marc. We’ll now open the call to any questions.
Question-and-Answer Session
Operator
[Operator Instructions] Our first question will come from Tao Qiu from Stifle.
Tao Qiu
Hey, good morning, you mentioned that you saw some improvement in collection towards the end of the second quarter. And DSO is down one day, in the second quarter, but still pretty much [anybody] [ph], how fast do you think you can get the number down in the next few quarters?
Marc Richards
Hey, Tao, it’s Marc Richards. How are you doing? I mean, that’s certainly the goal here in the third and fourth quarter, we’d expect improvement through the third quarter and into the fourth quarter. As you know, historically, our DSOs sit right around 50 days. So we still have work to do to shave that down to a normal cycles Tao.
Tao Qiu
Got it. In terms of pricing and could you give us an update on what kind of rate you are seeing, out there in terms of either Medicaid and commercial rates. I know that some states have increased their Medicaid rate, I think commercial payers are often more open to higher rate growth recovering inflation, any commentary you could provide it will be much appreciated. Thank you.
Charles Lynch
Hey, Tao, it’s Charlie. I don’t know that we saw anything in the quarter on the Medicaid side to call out. Our general expectation is something in the flattish range. And that’s generally how it came through. As Mark Ordan mentioned, we’re still in effectively business as usual related to managed care renewals and contracting. And as I’ve said in the past, our general view related to overall same unit, peer pricing, excluding the impacts of payer mix, or as we’ve seen in the first half of this year, some of the RCM matters, something in the modest range of 1% plus one to 2%. And digging through some of the impacts to our reported pricing this quarter we’re in that similar range.
Tao Qiu
Got you. If I may, squeeze in one more. Congrats on the rebranding efforts. I remember that during the pandemic, there was a delay of this initiative due to cost concerns. And what kind of G&A impact would this have on the second quarter, any lingering impact in the second half you’d expect here?
Charles Lynch
It actually had a very modest effect. If we had done so much of the work internally, we have a terrific Head of Marketing and a marketing team. And we had made a lot of the changes. So the incremental expense to formally change the name was negligible and I think is really going to have a galvanizing effect on the organization.
Tao Qiu
Got you. Thank you.
Operator
We’ll go next to the line of Brian Tanquilut with Jefferies.
Brian Tanquilut
Hey, good morning, guys. I guess Mark and Marc. Mark, just on the guidance, maybe without going into quarterly guidance any color or qualitative comments you can make for us to consider as we model Q3.
Mark Ordan
Sure. We were going into the quarter thinking that the 270 was the appropriate number. As I said, 270 is certainly achievable because of — I would say that the most major setbacks that we had was from the transition from R1 and the cost, it hits the revenue line item. But I look at it as a cost that was incurred in Q1 and to a lesser extent in Q2, and we’ll see how much of that we can recover, we’ve been working hard and we have a terrific team doing it, to know what that will shake out to by the end of the year. And then payer mix certainly fluctuates by quarter and then this quarter, it had a negative effect on us. So we felt that it’s analytically more appropriate to call to a range of 260 to 270. But we can’t say, we’re in that range will fall and again, depending on how we recover from the transition efforts that we described, that will have a major effect on where we end up.
Marc Richards
Brian, specific to your question on Q3, we expect quarter-over-quarter when looking back to Q3 of 21, growth quarter-over-quarter in the low single digits.
Brian Tanquilut
Got it. Okay, that’s very helpful. And then I guess, Mark, since you touched on payer mix. Do you think, are you seeing any signs that this is like the broader macro environment starting to show up in the payer mix? I mean, we saw this obviously, during the last recession. So just curious what you’re seeing maybe ahead of time?
Mark Ordan
No, we haven’t. No, we’re not seeing that. As a matter of fact, payer mix. And I know from other organizations, same thing payer mix can really fluctuate a lot. And not because of the pattern, there is no pattern that we see. That would indicate any shift or I would have called it out.
Brian Tanquilut
All right, got it. Thank you.
Operator
We’ll go next to the line of Kevin Fischbeck with Bank of America. Go ahead.
Kevin Fischbeck
Great, thanks. So I think you mentioned 10 million headwind in Q1 and 5 million in Q2 on the R1 transition. Is that 15 million kind of like something that we should think about as potentially coming back in and I guess in your guidance range? Is that like, how to think about the high and the low end of that range? Are there other factors besides how much of that you’re recouping?
Marc Richards
No, I would think of a component of that loss in the first half of the year, it’s gone. Some of it of course, is still recoverable and that’s what we’re parsing out right now.
Kevin Fischbeck
Okay. So that uncertainty on mix shift and then is there labor pressure, like how to think about if we thought at least 270 now being, let’s just — I’ll just say it this way, you’re not saying it this way, but at least 270 being at least 260? What other fact, were their main buckets besides that’s are we thinking about?
Mark Ordan
Labor is a relatively small factor. As I said, I called it out this time, because I didn’t want people to think that we’re not focused on the fact that we’re in a tough labor environment. We have a different labor mix than other — than hospitals do and others do. So I think that another factors make it hit us left. So the primary swing factors for 2022 that we see today are a combination of mix and what we can recover in the RCM transition process. Obviously, we don’t forecast what is going to be but we had solid gains in volume for the quarter. So all those things will determine where we are in that range.
Kevin Fischbeck
Okay. But it’s no change in your volume outlook, per se from last year through the other factors?
Marc Richards
No.
Kevin Fischbeck
And then on the labor side, you have a lot of different businesses, you’ve been expended different businesses, it would you say the labor is more difficult in any specific part of the business.
Mark Ordan
That’s not really something I would call out there. I mean, last time that we have a terrific recruiting arm and they integrate it. So we’ve done a very good job of keeping pace with turnover, and there’s no particular area that’s driving the increase in costs and the increase in costs are relatively modest, but I thought worth calling out, nonetheless.
Kevin Fischbeck
All right. Great. Thank you.
Operator
And we’ll move next to the line of Pito Chickering with Deutsche Bank.
Pito Chickering
Hey, good morning, guys. Thanks to taking my questions here. On that $50 million of charges sort of in the first half of the year due to R1. My understanding is that was simply the aging of receivables in a different buckets tends to charges. But you said that part of the first core component of $10 million is gone. Can you explain sort of why that’s gone? I thought that simply didn’t get a bill out into a payer hence is aged out a little unclear why it would not be recoverable when the R1 sort of caught up with the billings?
Marc Richards
Now, the component of that is denials and timely filings. So at any point in time, to the extent bills haven’t been set out, at that point in time, it’s a timing issue. If those bills are not set out, under the correct timing is dictated by your payer contracts, that money has been lost. So that’s a component I referred to.
Mark Ordan
And that plays into, just from based on experience, that is what effectively plays into the buckets of AR and we will reserve against them as they flow through.
Pito Chickering
Okay, fair enough. And then to follow up on Kevin’s question on the sort of the salary costs about $3 million above the forecast, I was under the impression that most of your physicians which are under multiyear contracts with both fixed and variable components. So you always are more insulated from some of these labor pressures. So I guess you are walking through where that $3 million sort of came from [indiscernible] because I guess I thought you actually been more excited in that.
Marc Richards
Yes. Pito, it’s, keep in mind, we’ve got in the 1000s of clinical providers across the organization. So as pleased as we are, with our general turnover rates there is still turnover, it’s relatively modest, but there is. So as we looked at the second quarter and dug into, you know, those individual practices, et cetera where there was a financial call out. The majority of instances were related to that modest level of turnover and open position that hadn’t yet been filled in the like, and thus, the need for either existing clinicians in that practice to take extra shifts on call overtime, and the like, prior to refilling that position. So in each one of those instances, obviously, there’s been a work plan. And we do think that there’s recapture there with some cost saving, but that is a general tone of how we saw in the quarter. And, again, as Mark mentioned, roughly $3 million run over versus our internal forecast is relatively minor.
Pito Chickering
All right. Last question here on pricing, just can you refresh us on where the out of network revenues are today, does this change sort of versus year end? And also on the government versus commercial payer mix? As you will think about potential environments so where are we today versus where we were in 2008? Thanks so much.
Mark Ordan
If I understand your question correctly, we continue to be overwhelmingly in network less than 5% of our — we are less with over 95% in network. So that hasn’t changed at all over the last two years. And as I said, we haven’t seen any, any pattern or change in behavior. While we wait for clarity from HHS, but I’m not sure that I answered exactly your question. Did I?
Pito Chickering
Yes. Then that’s from Friday networking. I guess the question is, as people are thinking about, different recessionary risks here. What’s our government commercial mix today? And where was that in ’08?
Marc Richards
I don’t know if I have stats from ’08 on hand right now. But I can speak to what our experience has been over the past four or five years. And from an absolute standpoint, in terms of the percent of our patient volume, as measured by gross charges on either the two sides, government or non-government, which is how we look at it, where we stand today, the government component is very comparable to where it’s been over the past couple of years. And actually, even for this quarter is maybe 100 bps or more lower than where it kind of topped out a call it about four years ago. And during that period as we view it, it is likely that employment growth through the middle and latter stages of economic expansion prior to the pandemic had a favorable role for us.
Operator
Next we’ll go to the line of Whit Mayo with SVB Securities.
Whit Mayo
Thanks. Maybe just to follow up on the payer mix question. I don’t know if you’ve disclosed this, but I was just curious what percent of your commercial revenues today are coming from patients on the exchanges?
Marc Richards
I don’t know if we’ve ever had a perfectly clean view on that Whit because generally, and even going back to the initiation of the exchanges, oftentimes, we would be submitting a claim to the same carrier, whether it was exchange program or not. So we’ve never had a perfectly clear view of ACA volume. But that said, in general, any kind of contracts we had that covered that were under the existing contract we have with the payer. So they had an exchange program or a normal insurance program, our contracts were comparable.
Whit Mayo
I guess maybe to ask it in a different way. If you look at go back to 2014 and did you see an uptick in maybe your commercial mix, where that could be attributed to exchange patients? I’m just trying to get a sense of sort of how you guys think about that.
Mark Ordan
I think, Whit we will get back to you on that.
Marc Richards
Yes. By my recollection, we didn’t. But we can track back. I don’t remember being anything.
Whit Mayo
That’s fair. I’m just trying to, obviously, think about like if the subsidies go away, what the potential headwind could be if there is a headwind. But the other question United has a notice on their website that indicates that you may be out of network in Georgia in 2023. I’m sure you probably can’t discuss this. But maybe there’s nothing abnormal about this. I presume this is just ongoing negotiation. So I just thought I’d ask if there’s anything to talk about there. And then really a final question, just on the G&A target 250. Are you feeling any better or worse about that?
Mark Ordan
On the first, we wouldn’t comment on that, there’s normal negotiating processes with all of our payers, we have over 500 contracts. And I’m aware of that. So there’s nothing else that wheel into that. And our G&A targets, yes, we’re comfortable with what we’ve laid out.
Whit Mayo
Okay. Thanks, guys. Appreciate it.
Operator
We’ll go next to Ryan Daniels with William Blair.
UnidentifiedAnalyst
Hey, guys, This is Jack [indiscernible] on for Daniels. Thanks for taking my question. I just have one quick question. I think all my other questions are really been answered. So I know the Brave integration wasn’t an outright acquisition. But kind of given the inflationary environment and other current market conditions with rising rates, et cetera. Do you have any update on the acquisition pipeline and possible investments? I guess, just to kind of rephrase this, what’s your mindset when it comes to M&A and investments like Brave, are you kind of looking at areas to supplement growth on the urgent care side more technology, investments, et cetera. Any color you have on that would be appreciated?
Mark Ordan
Well, not to sound too vague. We were excited to grow in any area where it fits our core business, and where it’s accretive. So in many of our subspecialties, we’re actively looking at ways to increase footprint. We’d like to grow in serving NICUs a lot of my time and Swift time is spent with our hospital systems and prospective hospital partners to find ways to increase. Certainly in primary and urgent care, you mentioned Brave we acquired outright of NightLight of Orlando and NightLight of Houston. And we will look at both de novo growth and also acquisition gross. And we think both of those we can do without undue pressure on using our cash flow.
And as we mentioned, which I think is very important. We were also able to buy back 3.3 million shares of our stock with all of this without changing like debt levels at all. So we are eager to grow when there are opportunities. Some of it the lack of clarity from HHS, probably informed. Some lack but we’re still and out there.
UnidentifiedAnalyst
Perfect. Thanks.
Operator
[Operator Instructions] We’ll go to the line of AJ Rice with Credit Suisse. Go ahead.
AJ Rice
Hi, thanks. Hello, everybody. A couple of things. Obviously, the step up on the buybacks, I wanted to ask you about that? Is that an opportunistic valued in the second quarter or should we begin to think that you’re going to commit more capital to that going forward?
Mark Ordan
Well, I have the classic CEO answer. These are the kind of decisions that we work closely with our Board. And when we think is a strong use of capital, that’s where we put our capital. And we felt — the Board felt unanimously that this was a good time to be buying back our shares. So I can’t comment on future activity.
AJ Rice
Okay. A lot of back and forth on the R1 transition and the impact it’s had on revenues today. I wondered within the context of that. I’m not 100% clear, is that something you would characterize as just what can happen when you make a transition like this? Do you feel like, are ones drop the ball, was there something you did that has resulted in this? And is there any recourse to try to — do they owe you any kind of concession because this has happened?
Mark Ordan
I said in my comments that we had in retrospect moved too abruptly. So I’d say we had an RCM team, big RCM team, and in the move from RCM team to R1, I’d say with hindsight, which is always handy. We should have retained our team longer to give R1 more time to get up to speed. And we did that more abruptly. That’s what I mean, by more abruptly than I wish we had.
There’s no recourse to R1. And I would say it just collectively it didn’t go as smoothly as we had hoped. And now this is the kind of thing that can happen. We have an enormous RPM function. So I think we did it, we did it pretty well, but not as well as I wish we had. Having said that, importantly, we’re at a point. We’re at a point today, where we have a very solid RCM function. And as I mentioned, in addition to that we have an arbitration capability that we would never have been able to match on our own.
So as Marc rightly pointed out that the other side of the RCM effort right now is collecting as much as we can, from the earlier month to recover as much as possible. But I think that it was a very good transition, a very good move to transition to R1. We’re not disappointed with our decision at all. We’re disappointed by the turbulence and by the fact that had we — we believe that we kept people on our team longer, it would have been a better transition and less costly for us.
AJ Rice
Okay. You did mention with respect to No Surprise Act in your comments that you’ve geared up your team to be able to deal with any arbitration issues that might result. I just wondered if — are you seeing is that gearing up for some of them may happen? Are you actually seeing more cases go to an arbitration at this point? Or was your arbitration to be more?
Mark Ordan
We are overwhelmingly in network, so we haven’t seen the increase in arbitration, the only areas where we’re out of network, and we have had arbitration, we’ve been very pleased with the results. But we know that one of these days there will be a — there will be some final ruling, and things will settle in and we will need to have a process to settle these in arbitration.
AJ Rice
And it doesn’t sound like you’re seeing any delay in MCL recontracting as people are waited for those final rules to come out. Is this just sort of normal course. It sounds like it’s the way you’re describing it. Is that correct?
Mark Ordan
Yes, that’s correct. And I would say the latter part of last year people were — a lot of people were expecting it to be a much tougher environment. We haven’t certainly to date we haven’t seen that.
AJ Rice
All right. And just my last area, just quick question is on the push for the pediatric urgent care centers. Obviously, you’ve known some of them for a little while now. Anything developing either making you more or less optimistic about the economics of that business and the opportunity set. And a lot of this during COVID was put in place. And maybe parents were saying, “Hey, I’d go to a pediatric urgent care center, because I want to keep my kids away from, places where they might catch COVID from adults.” Are you seeing any change in the demand profile as we progress through the pandemic?
Mark Ordan
We weren’t basing our decision on what we saw at the time was a COVID bump like any acquisition, you look not only at what’s going on at the moment, but what’s going on — what went on historically. So we weren’t moving into this because of a COVID froth in earnings. So no, we continued to be very pleased with the P&L of these of these operations and the economic opportunity and our thinking about it hasn’t changed. If there are times when there’s a upward blip because of a COVID, which obviously, for all reasons, you don’t want another COVID. But obviously, that’s not the driver of our reason to do this.
Our reason to do this is, as it’s always been that we are in our major markets, the largest employer of pediatricians, we have an enormous impact on what happens in pediatric care in our markets. And we think that this is a very important step to filling out our ability to help mothers and babies and children.
AJ Rice
Okay. That’s great. Thanks so much.
Operator
We have a follow up question from the line of Kevin Fischbeck with Bank of America.
Kevin Fischbeck
Great, thanks. I just wanted to get maybe a little more color about what you mean about the arbitration improvements with R1, what exactly are you guys have in place now that maybe you wouldn’t have been able to do before?
Mark Ordan
Well, the arbitration process right now is only where we are out of network. And we’re the only place where we’re principally out of network is in Texas. And I would say that we have the arbitration process, which many people don’t know, is a case-by-case process. So you could imagine how laborious a process like that could be, if it ever became significant. So you have to have a machine in place to handle that and to handle that intelligently. And I think we have that today with thanks to our partnership with our team, our managed care team and R1. And I think that would have been very difficult to build on our own.
Kevin Fischbeck
Okay. I guess do you have a sense about where your pricing is versus kind of meeting in network. My assumption is that if you’re out of network, almost definitionally, it’s because you’d be above the median in network rate. So I guess in that 5%, there might be some risk, but broadly speaking, any way to think about that?
Mark Ordan
We don’t. It varies payer by payer and contract by contract, so I don’t have that.
Kevin Fischbeck
Okay, great. Thanks.
Operator
And gentlemen, we have no further lines in queue at this time.
Mark Ordan
Great, well, thank you all, for your understanding, your support and we look forward to updating you on our progress as we move forward. Enjoy the rest of your summer.
Operator
Ladies and gentlemen, that will conclude your conference call for today. Thank you for your participation and for using AT&T Event Teleconferencing. You may now disconnect.
Be the first to comment